Evaluating Smoking Cessation Interventions for PWH in South Africa

Recruiting Phase 2 Phase 3 Interventional Study
Smoking Cessation HIV Comorbidities and Coexisting Conditions
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
660 (estimated)
Sponsor
Johns Hopkins University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. ≥18 years of age, and 2. attend one of the selected study clinics, and 3. have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documen…
Contacts

Jonathan E Golub, PhD MPH

443-287-2969

jgolub@jhmi.edu

CONTACT

Laura Steiner, MSc

410-424-8445

lsteine5@jhmi.edu

CONTACT